Efficacy of a New Pulmonary Cyclosporine A Powder Formulation for Prevention of Transplant Rejection in Rats

Journal of Heart and Lung Transplantation

Volumn 28, Issue 5, 2009, Pages 486-492

  Zijlstra, Gerrit S ^a   Wolting, Joske ^a   Prop, Jochum ^a   Petersen, Arjen H ^a   Hinrichs, Wouter L J ^a   Uges, Donald R A ^b   Kerstjens, Huib A M ^b   van der Bij, Wim ^b   Frijlink, Henderik W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; GRAFT REJECTION; HISTOPATHOLOGY; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LUNG VENTILATION; MALE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; SCORING SYSTEM; X RAY PICTURE;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUNG; LUNG TRANSPLANTATION; MALE; POWDERS; RATS; RATS, INBRED STRAINS;

EID: 67349249373     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.02.001     Document Type: Article

References (30)

1. Kobashigawa J.A., Patel J., Furukawa H., et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 25 (2006) 434-439
2. Glanville A.R., Aboyoun C.L., Morton J.M., et al. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation. J Heart Lung Transplant 25 (2006) 928-934
3. Jaksch P., Kocher A., Neuhauser P., et al. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). J Heart Lung Transplant 24 (2005) 1076-1080
4. Barnard J.B., Thekkudan J., Richardson S., et al. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation. J Heart Lung Transplant 25 (2006) 564-568
5. Akhlaghi F., Gonzalez L., and Trull A.K. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. J Heart Lung Transplant 24 (2005) 2120-2128
6. Rosenberg P.B., Vriesendorp A.E., Drazner M.H., et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 24 (2005) 1327-1331
7. Valantine H., and Zuckermann A. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. J Heart Lung Transplant 24 suppl (2005) S185-S190
8. Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation?. Lessons learned from renal transplantation and oncology. J Heart Lung Transplant 26 (2007) 557-564
9. Ross H., Pflugfelder P., Haddad H., et al. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. J Heart Lung Transplant 27 (2008) 197-202
10. Kovarik J.M., Snell G.I., Valentine V., et al. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. J Heart Lung Transplant 25 (2006) 440-446
11. Vigano M., Tuzcu M., Benza R., et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 26 (2007) 584-592
12. Hummel M. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference. J Heart Lung Transplant 24 suppl (2005) S196-S200
13. Iacono A.T., Smaldone G.C., Keenan R.J., et al. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am J Respir Crit Care Med 155 (1997) 1690-1698
14. Iacono A.T., Johnson B.A., Grgurich W.F., et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 354 (2006) 141-150
15. Blot F., Tavakoli R., Sellam S., et al. Nebulized cyclosporine for prevention of acute pulmonary allograft rejection in the rat: pharmacokinetic and histologic study. J Heart Lung Transplant 14 (1995) 1162-1172
16. Zenati M., Duncan A.J., Burckart G.J., et al. Immunosuppression with aerosolized cyclosporine for prevention of lung rejection in a rat model. Eur J Cardiothorac Surg 5 (1991) 266-271
17. Keenan R.J., Duncan A.J., Yousem S.A., et al. Improved immunosuppression with aerosolized cyclosporine in experimental pulmonary transplantation. Transplantation 53 (1992) 20-25
18. Corcoran T.E., Smaldone G.C., Dauber J.H., et al. Preservation of post-transplant lung function with aerosol cyclosporin. Eur Respir J 23 (2004) 378-383
19. Gilbert S., Dauber J.H., Hattler B.G., et al. Lung and heart-lung transplantation at the University of Pittsburgh: 1982-2002. Clin Transplant (2002) 253-261
20. Iacono A.T., Corcoran T.E., Griffith B.P., et al. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J 23 (2004) 384-390
21. Burkart G.J., Smaldone G.C., Eldon M.A., et al. Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. Pharm Res 20 (2003) 252-256
22. Zijlstra G.S., Rijkeboer M., Jan van Drooge D., et al. Characterization of a cyclosporine solid dispersion for inhalation. AAPS J 9 (2007) E190-E199
23. Le Brun P.P.H., de Boer A.H., Mannes G.P., et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 54 (2002) 25-32
24. Prop J., Ehrie M.G., and Crapo J.D. Reimplantation response in isografted rat lungs. Analysis of causal factors. J Thorac Cardiovasc Surg 87 (1984) 702-711
25. Marck K.W., Prop J., Wildevuur C.R., and Nieuwenhuis P. Lung transplantation in the rat: histopathology of left lung iso- and allografts. J Heart Transplant 4 (1985) 263-266
26. Wang P.P., Simpson E., Meucci V., et al. Cyclosporine monitoring by fluorescence polarization immunoassay. Clin Biochem 24 (1991) 55-58
27. Nedelman J.R., Gibiansky E., and Lau D.T. Applying Bailer's method for AUC confidence intervals to sparse sampling. Pharm Res 12 (1995) 124-128
28. Mitruka S.N., Pham S.M., Zeevi A., et al. Aerosol cyclosporine prevents acute allograft rejection in experimental lung transplantation. J Thorac Cardiovasc Surg 115 (1998) 28-36
29. Mitruka S.N., Won A., McCurry K.R., et al. In the lung aerosol cyclosporine provides a regional concentration advantage over intramuscular cyclosporine. J Heart Lung Transplant 19 (2000) 969-975
30. Wu C.Y., Benet L.Z., Hebert M.F., et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58 (1995) 492-497